KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibreGüncel ima edilen olasılıkbefore April 2027 81%6 seçenek arasında lider
Piyasa kalitesi
34 / 100
Düşük kalite24s Hacim
₺268,5
Likidite
₺169 B
Orta likiditeAlis / Satis
60.0% / 69.0%
Spread
9.0 pt
Geniş spreadPiyasa verileri
27 dakika önce guncellendi
24 Mar 26 14:001 Kas 26 5:00
Trendler
Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir
Seçilen sonuç
before November69%
Hacim trendi
$62 Tem20g veri27 Tem
İlgili Piyasalar
Testosterone unscheduled/rescheduled more permissively in US by end of 2028?
₺27,5 BEvet: 17.8%MANIFOLD MARKETS
MANIFOLD MARKETS2026 Ebola epidemic deaths?
₺27 B<250: 0.2%MANIFOLD MARKETS
MANIFOLD MARKETSWill there be a cure for schizophrenia before 2032?
₺23,7 BEvet: 11.8%MANIFOLD MARKETS
MANIFOLD MARKETS
Hantavirus vaccine in 2026?
₺49,7Evet: 6%
POLYMARKET
POLYMARKET
Will there be a year without polio before 2030?
₺0Evet: 11%KALSHI
KALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?
₺0before September: 15%KALSHI
KALSHIBu konularda aktif
İlgili Haberler
Crypto is the canary in the coal mine for the quantum computing threat, experts sayCoindesk
Galaxy Digital opens $5M fund for Bitcoin quantum security researchCrypto News
Claude's Fable 5 just solved an 87-year-old math problem, and it matters for bitcoinCoindesk
Google DeepMind, Isomorphic Labs Unveil AI-Powered Bioresilience PlanBlockchain.News
NVIDIA's Ising Decoder Slashes Color Code Errors 300xBlockchain.News
NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.NewsKurallar
If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.